Article Text

Download PDFPDF
Purinergic receptors as future targets for treatment of functional GI disorders
  1. Geoffrey Burnstock
  1. Professor Geoffrey Burnstock, Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK; g.burnstock{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The concept of purinergic signalling arose from experiments designed to find the identity of the non-adrenergic, non-cholinergic (NANC) inhibitory neurotransmitter in the gut.1 However, it has taken many years for the more general importance of the various roles of ATP as a physiological messenger in the gut to be recognised. Later, after the concept of co-transmission was established, ATP, nitric oxide and vasoactive intestinal polypeptide were recognised as co-transmitters in NANC nerves, although the proportions vary in different gut regions. Following cloning experiments in the early 1990s, four subtypes of P1 (adenosine) receptors, seven subtypes of P2X ion channel receptors and eight subtypes of P2Y G-protein-coupled receptors have been recognised.2 Many of these purinoceptor subtypes have been identified on the myenteric, submucosal motor, sensory and interneurons involved in synaptic …

View Full Text


  • Competing interests: None.

Linked Articles